Hollencrest Securities Has Cut Gilead Sciences (GILD) Stake By $411,800; Daruma Capital Management Has Cut Natus Medical Del (BABY) Stake

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Hollencrest Securities Llc decreased Gilead Sciences Inc (GILD) stake by 64.28% reported in 2017Q4 SEC filing. Hollencrest Securities Llc sold 5,800 shares as Gilead Sciences Inc (GILD)’s stock rose 1.93%. The Hollencrest Securities Llc holds 3,223 shares with $231,000 value, down from 9,023 last quarter. Gilead Sciences Inc now has $98.76B valuation. The stock increased 0.82% or $0.61 during the last trading session, reaching $75.39. About 5.69M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since March 30, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Daruma Capital Management Llc decreased Natus Medical Inc Del (BABY) stake by 6.49% reported in 2017Q4 SEC filing. Daruma Capital Management Llc sold 89,896 shares as Natus Medical Inc Del (BABY)’s stock declined 13.23%. The Daruma Capital Management Llc holds 1.30 million shares with $49.49M value, down from 1.39M last quarter. Natus Medical Inc Del now has $1.10 billion valuation. The stock increased 1.82% or $0.6 during the last trading session, reaching $33.65. About 689,840 shares traded or 19.09% up from the average. Natus Medical Incorporated (NASDAQ:BABY) has declined 13.34% since March 30, 2017 and is downtrending. It has underperformed by 24.89% the S&P500.

Since March 2, 2018, it had 0 insider purchases, and 1 insider sale for $126,700 activity. Shares for $126,700 were sold by LUDLUM KEN on Friday, March 2.

Analysts await Natus Medical Incorporated (NASDAQ:BABY) to report earnings on April, 25. They expect $0.24 EPS, down 20.00% or $0.06 from last year’s $0.3 per share. BABY’s profit will be $7.87M for 35.05 P/E if the $0.24 EPS becomes a reality. After $0.42 actual EPS reported by Natus Medical Incorporated for the previous quarter, Wall Street now forecasts -42.86% negative EPS growth.

Investors sentiment decreased to 0.71 in Q4 2017. Its down 0.05, from 0.76 in 2017Q3. It worsened, as 19 investors sold BABY shares while 78 reduced holdings. 27 funds opened positions while 42 raised stakes. 30.91 million shares or 1.01% more from 30.60 million shares in 2017Q3 were reported. Callahan Advsrs Ltd Liability Com has 5,935 shares. Moreover, Piedmont Invest Advsrs Ltd Liability has 0% invested in Natus Medical Incorporated (NASDAQ:BABY) for 6,404 shares. Cubist Systematic Strategies Limited Liability reported 5,856 shares stake. Amer invested in 0.02% or 9,125 shares. Blackrock Inc invested 0.01% of its portfolio in Natus Medical Incorporated (NASDAQ:BABY). Polaris Capital Limited Liability Corp invested in 66,220 shares. 12,526 were reported by Gsa Capital Llp. Hotchkis And Wiley Cap Llc holds 0% of its portfolio in Natus Medical Incorporated (NASDAQ:BABY) for 9,703 shares. Moreover, Comerica Bancshares has 0.01% invested in Natus Medical Incorporated (NASDAQ:BABY) for 32,171 shares. Riverhead Capital Mgmt Limited Liability Corporation owns 3,837 shares or 0.01% of their US portfolio. Barclays Public Limited Company accumulated 45,971 shares. Alphaone Inv Ltd Co stated it has 0.74% of its portfolio in Natus Medical Incorporated (NASDAQ:BABY). 40,459 are held by Ny State Common Retirement Fund. Sei stated it has 0% in Natus Medical Incorporated (NASDAQ:BABY). Cambiar Investors Ltd Co reported 234,817 shares.

Daruma Capital Management Llc increased Texas Capital Bancshares Inc (NASDAQ:TCBI) stake by 5,060 shares to 611,870 valued at $54.40 million in 2017Q4. It also upped Superior Energy Svcs Inc (NYSE:SPN) stake by 217,957 shares and now owns 437,577 shares. Monotype Imaging Holdings In (NASDAQ:TYPE) was raised too.

Among 5 analysts covering Natus Medical (NASDAQ:BABY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Natus Medical had 11 analyst reports since July 23, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, February 27 by Roth Capital. The rating was maintained by Roth Capital with “Buy” on Tuesday, April 5. The rating was maintained by Roth Capital on Monday, September 11 with “Buy”. As per Thursday, July 23, the company rating was maintained by TH Capital. Roth Capital maintained the stock with “Buy” rating in Friday, June 23 report. Raymond James upgraded Natus Medical Incorporated (NASDAQ:BABY) on Tuesday, September 13 to “Outperform” rating. The company was initiated on Tuesday, October 4 by Benchmark. William Blair downgraded Natus Medical Incorporated (NASDAQ:BABY) on Monday, January 8 to “Hold” rating. TH Capital maintained Natus Medical Incorporated (NASDAQ:BABY) rating on Thursday, October 22. TH Capital has “Buy” rating and $53 target. Raymond James downgraded Natus Medical Incorporated (NASDAQ:BABY) on Thursday, February 2 to “Mkt Perform” rating.

Since October 2, 2017, it had 0 buys, and 16 selling transactions for $43.10 million activity. Shares for $467,138 were sold by Cogan John Francis on Friday, March 16. Shares for $6.05 million were sold by MARTIN JOHN C. Shares for $1.18 million were sold by Alton Gregg H on Tuesday, February 20. $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Meyers James R. Washington Robin L also sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. $4.68M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by WILSON GAYLE E.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1. They expect $1.59 EPS, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.08B for 11.85 P/E if the $1.59 EPS becomes a reality. After $1.60 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Needham on Wednesday, July 29 with “Buy”. The firm has “Market Perform” rating given on Friday, December 4 by Wells Fargo. On Friday, July 29 the stock rating was downgraded by Argus Research to “Hold”. The company was maintained on Wednesday, January 3 by Credit Suisse. Mizuho maintained it with “Buy” rating and $77.0 target in Thursday, September 28 report. BMO Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, October 27 with “Outperform” rating. Wells Fargo maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, January 29 with “Buy” rating. As per Wednesday, September 9, the company rating was initiated by Jefferies. The firm has “Buy” rating by Gabelli given on Wednesday, June 1. The stock has “Buy” rating by Berenberg on Thursday, September 22.

Hollencrest Securities Llc increased Select Sector Health Care Spdr (XLV) stake by 4,162 shares to 191,556 valued at $15.84 million in 2017Q4. It also upped Spdr S&P Dividend Etf (SDY) stake by 10,776 shares and now owns 44,393 shares. Vanguard S&P 500 Etf (VOO) was raised too.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It turned negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Cornerstone Capital has 62,966 shares for 0.77% of their portfolio. Advantus invested 0.24% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Cwm Ltd Llc holds 0.26% in Gilead Sciences, Inc. (NASDAQ:GILD) or 83,213 shares. Wg Shaheen And Associate Dba Whitney And has invested 0.85% in Gilead Sciences, Inc. (NASDAQ:GILD). Nuveen Asset Management Limited Liability reported 976,403 shares stake. Bb&T has 0.32% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 235,660 shares. Ahl Llp holds 114,529 shares. Sumitomo Mitsui Hldgs stated it has 3.85M shares. Nippon Life Glob Americas invested 1.82% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Metropolitan Life Ins Com, a New York-based fund reported 242,547 shares. Klingenstein Fields & Company Limited Liability Company, a New York-based fund reported 19,520 shares. Verition Fund Mngmt Llc stated it has 0.16% in Gilead Sciences, Inc. (NASDAQ:GILD). Jefferies Grp Ltd Liability Corp has 10,622 shares for 0% of their portfolio. Fagan Assoc Inc stated it has 34,594 shares or 1% of all its holdings. Asset Inc accumulated 18,289 shares or 0.18% of the stock.

Natus Medical Incorporated (NASDAQ:BABY) Institutional Positions Chart